HOW TO MOVE TOWARDS PRECISION I-O? INNOVATION IN BIOMARKER R&D

Old data, new tools: leveraging routinely acquired patient data to address current challenges in I–O

Immuno-Oncology Insights 2022; 3(7), 359–365

DOI: 10.18609/ioi.2022.038

Published: 3 August 2022
Interview
Dr Anant Madabhushi


Better predicting which patients will respond to checkpoint inhibitors remains a critical challenge for the I–O field. Biomedical engineer and AI expert Anant Madabhushi discusses how combining routine patient data with the power of computational tools can help to address the problem – and why he chose to take an ‘anti-black box’ AI approach.


Anant Madabhushi is a Professor of Biomedical Engineering; and on faculty in the Departments of Pathology, Biomedical Informatics, and Radiology and Imaging Sciences at Emory University. He is also a Research Health Scientist at the Atlanta Veterans Administration Medical Center. Dr Madabhushi has authored more than 450 peer-reviewed publications and more than 100 patents issued or pending. He is a, Fellow of the American Institute of Medical and Biological Engineering (AIMBE), and the Institute for Electrical and Electronic Engineers (IEEE) and the National Academy of Inventors (NAI). His work on ‘Smart Imaging Computers for Identifying lung cancer patients who need chemotherapy’ was called out by Prevention Magazine as one of the top 10 medical breakthroughs of 2018. In 2019, Nature hailed him as one of five scientists developing “offbeat and innovative approaches for cancer research”. Dr Madabhushi was named to The Pathologist’s Power List in 2019, 2020, 2021 and 2022.